Indian multinational pharmaceutical company, Zydus Lifesciences Limited, has received final approval from the United States ...

Zydus Lifesciences share price extended the gains on second day, rising 1 percent in the early trade on April 15 following United States Food and Drug Administration (USFDA) approval for Jaythari ...

Zydus Lifesciences Limited has earned USFDA approval for Niacin Extended-Release Tablets used to treat high cholesterol.

New Delhi: Indian multinational pharmaceutical company, Zydus Lifesciences Limited, has received final approval from the ...

The company on April 11 informed that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) Tablets. Deflazacort is a ...

Zydus Lifesciences has some good news — it has received final USFDA approval to sell Jaythari (Deflazacort) Tablets in America. This drug helps treat Duchenne muscular dystrophy (DMD ...

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the latest treatment advancements for Duchenne muscular dystrophy.

The positive trend in GIFT Nifty index also indicates a gap-up opening for domestic benchmark indices BSE Sensex and NSE Nifty50. AT 8:15 AM, the GIFT Nifty futures were up 264 points, or 1.13%, ...

Zydus Lifesciences: The pharma company has received final approval from the USFDA to manufacture Jaythari (Deflazacort) tablets, available in 6 mg, 18 mg, 30 mg, and 36 mg strengths. Deflazacort ...